In Brief: Ciba/Chiron Aredia
Executive Summary
Ciba/Chiron Aredia: Receives supplemental approval from FDA for treatment of osteolytic bone metastases of breast cancer July 16. Aredia (pamidronate disodium) was recommended for the indication by FDA's Oncologic Drugs Advisory Committee on June 13 ("The Pink Sheet" June 17, p. 7)...